Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

1.

The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension.

Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T, Richter Y, Zaaroor-Regev D, Manor Y, Weizman A.

Eur Psychiatry. 2012 Jul;27(5):335-42. doi: 10.1016/j.eurpsy.2011.05.004. Epub 2011 Jul 31.

PMID:
21807480
[PubMed - indexed for MEDLINE]
2.

Safety of phosphatidylserine containing omega3 fatty acids in ADHD children: a double-blind placebo-controlled trial followed by an open-label extension.

Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T, Richter Y, Zaaroor-Regev D, Manor Y, Weizman A.

Eur Psychiatry. 2013 Aug;28(6):386-91. doi: 10.1016/j.eurpsy.2012.11.001. Epub 2013 Jan 9.

PMID:
23312676
[PubMed - indexed for MEDLINE]
4.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.

Pediatrics. 2004 Jul;114(1):e1-8.

PMID:
15231966
[PubMed - indexed for MEDLINE]
5.

Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.

Boellner SW, Earl CQ, Arora S.

Curr Med Res Opin. 2006 Dec;22(12):2457-65.

PMID:
17257460
[PubMed - indexed for MEDLINE]
6.

Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.

Connor DF, Findling RL, Kollins SH, Sallee F, López FA, Lyne A, Tremblay G.

CNS Drugs. 2010 Sep;24(9):755-68. doi: 10.2165/11537790-000000000-00000.

PMID:
20806988
[PubMed - indexed for MEDLINE]
7.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
[PubMed - indexed for MEDLINE]
8.

Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.

Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang JG, Biederman J.

J Clin Psychiatry. 2006 Jan;67(1):137-47.

PMID:
16426100
[PubMed - indexed for MEDLINE]
9.

Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.

Bilici M, Yildirim F, Kandil S, Bekaroğlu M, Yildirmiş S, Değer O, Ulgen M, Yildiran A, Aksu H.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):181-90.

PMID:
14687872
[PubMed - indexed for MEDLINE]
10.

A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study.

Biederman J, Swanson JM, Wigal SB, Boellner SW, Earl CQ, Lopez FA; Modafinil ADHD Study Group.

J Clin Psychiatry. 2006 May;67(5):727-35.

PMID:
16841622
[PubMed - indexed for MEDLINE]
11.

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.

Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N; SPD503 Study Group.

Pediatrics. 2008 Jan;121(1):e73-84. doi: 10.1542/peds.2006-3695.

PMID:
18166547
[PubMed - indexed for MEDLINE]
Free Article
12.

Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.

Greenhill LL, Muniz R, Ball RR, Levine A, Pestreich L, Jiang H.

J Am Acad Child Adolesc Psychiatry. 2006 Jul;45(7):817-23.

PMID:
16832318
[PubMed - indexed for MEDLINE]
13.

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.

Cheng JY, Chen RY, Ko JS, Ng EM.

Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Epub 2007 Jun 16.

PMID:
17572882
[PubMed - indexed for MEDLINE]
14.

Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension.

Vakhapova V, Richter Y, Cohen T, Herzog Y, Korczyn AD.

BMC Neurol. 2011 Jun 28;11:79. doi: 10.1186/1471-2377-11-79.

PMID:
21711517
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.

Brams M, Muniz R, Childress A, Giblin J, Mao A, Turnbow J, Borrello M, McCague K, Lopez FA, Silva R.

CNS Drugs. 2008;22(8):693-704.

PMID:
18601306
[PubMed - indexed for MEDLINE]
17.

Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.

Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A; LYCY Study Group.

Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28.

PMID:
19716683
[PubMed - indexed for MEDLINE]
18.

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder.

Biederman J, Lopez FA, Boellner SW, Chandler MC.

Pediatrics. 2002 Aug;110(2 Pt 1):258-66.

PMID:
12165576
[PubMed - indexed for MEDLINE]
19.

Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.

Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ; Atomoxetine ADHD Study Group.

Pediatrics. 2002 Dec;110(6):e75.

PMID:
12456942
[PubMed - indexed for MEDLINE]
20.

Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder.

Sallee FR, Kollins SH, Wigal TL.

J Child Adolesc Psychopharmacol. 2012 Jun;22(3):206-14. doi: 10.1089/cap.2010.0135. Epub 2012 May 21.

PMID:
22612526
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk